BACKGROUND: Intestinal-type sinonasal adenocarcinoma (ITAC) is a rare tumor etiologically related to professional exposure to wood dust. The overall prognosis is poor, mainly due to the difficulty to resect the tumor completely in this anatomically complex region. Therefore, there is great need for alternative treatments. However, the lack of a good tumor model system for ITAC has hampered the development and testing of new therapeutic agents. Here, we report the establishment and characterization of the first human ITAC cell line named ITAC-3. METHODS: The cell line was initiated from small explants of a T4bN0M0 colonic type ITAC from the ethmoid sinus. Growth and invasion parameters as well as genetic characteristics were analyzed. RESULTS: The population doubling time was 18 h and the cell line was capable of invasion in matrigel. Chromosomal analysis showed a tetraploid karyotype with both numerical and structural aberrations. High resolution microarray CGH analysis identified many copy number alterations, including homozygous deletions. TP53 carried a mutation c.818G>T in exon eight concurring with a strong nuclear protein overexpression. Immunohistochemical analysis showed protein overexpression of EGFR and normal expression of β-catenin and p16. CONCLUSION: This is the first report of the establishment of a cell line derived from a primary ITAC. The genomic profile of the cell line was the same as the primary tumor from which it was derived. This new cell line will be a useful tool for the development and testing of new therapeutic agents for this tumor type.
BACKGROUND:Intestinal-type sinonasal adenocarcinoma (ITAC) is a rare tumor etiologically related to professional exposure to wood dust. The overall prognosis is poor, mainly due to the difficulty to resect the tumor completely in this anatomically complex region. Therefore, there is great need for alternative treatments. However, the lack of a good tumor model system for ITAC has hampered the development and testing of new therapeutic agents. Here, we report the establishment and characterization of the first human ITAC cell line named ITAC-3. METHODS: The cell line was initiated from small explants of a T4bN0M0 colonic type ITAC from the ethmoid sinus. Growth and invasion parameters as well as genetic characteristics were analyzed. RESULTS: The population doubling time was 18 h and the cell line was capable of invasion in matrigel. Chromosomal analysis showed a tetraploid karyotype with both numerical and structural aberrations. High resolution microarray CGH analysis identified many copy number alterations, including homozygous deletions. TP53 carried a mutation c.818G>T in exon eight concurring with a strong nuclear protein overexpression. Immunohistochemical analysis showed protein overexpression of EGFR and normal expression of β-catenin and p16. CONCLUSION: This is the first report of the establishment of a cell line derived from a primary ITAC. The genomic profile of the cell line was the same as the primary tumor from which it was derived. This new cell line will be a useful tool for the development and testing of new therapeutic agents for this tumor type.
Authors: L Licitra; S Suardi; P Bossi; L D Locati; L Mariani; P Quattrone; S Lo Vullo; M Oggionni; P Olmi; G Cantù; M A Pierotti; S Pilotti Journal: J Clin Oncol Date: 2004-12-15 Impact factor: 44.544
Authors: Rebecca J Leary; Jimmy C Lin; Jordan Cummins; Simina Boca; Laura D Wood; D Williams Parsons; Siân Jones; Tobias Sjöblom; Ben-Ho Park; Ramon Parsons; Joseph Willis; Dawn Dawson; James K V Willson; Tatiana Nikolskaya; Yuri Nikolsky; Levy Kopelovich; Nick Papadopoulos; Len A Pennacchio; Tian-Li Wang; Sanford D Markowitz; Giovanni Parmigiani; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu Journal: Proc Natl Acad Sci U S A Date: 2008-10-13 Impact factor: 11.205
Authors: F X Roux; D Brasnu; B Devaux; E Chabardes; G Schwaab; O Laccourreye; M Menard; F Janot; S Nguyen; J Bertrand Journal: Surg Neurol Date: 1994-08
Authors: Manuela Ariza; José Luis Llorente; Cesar Alvarez-Marcas; Lucia Baragaño; Ana Salas; Nuria Rodriguez Prado; Mario Hermsen; Carlos Suárez; Andres Sampedro Journal: Cancer Date: 2004-01-15 Impact factor: 6.860
Authors: Cristina García-Inclán; Fernando López; Jhudit Pérez-Escuredo; Mari Paz Cuesta-Albalad; Blanca Vivanco; Irene Centeno; Milagros Balbín; Carlos Suárez; José Luis Llorente; Mario A Hermsen Journal: Cell Oncol (Dordr) Date: 2012-10-11 Impact factor: 6.730
Authors: Yoko Takahashi; Michael E Kupferman; Diana Bell; Tilahun Jiffar; June Goo Lee; Tong-Xin Xie; Ning-Wei Li; Mei Zhao; Mitchell J Frederick; Alexander Gelbard; Jeffrey N Myers; Ehab Y Hanna Journal: Clin Cancer Res Date: 2012-10-02 Impact factor: 12.531
Authors: Rebecca A Rowehl; Stephanie Burke; Agnieszka B Bialkowska; Donald W Pettet; Leahana Rowehl; Ellen Li; Eric Antoniou; Yuanhao Zhang; Roberto Bergamaschi; Kenneth R Shroyer; Iwao Ojima; Galina I Botchkina Journal: PLoS One Date: 2014-06-12 Impact factor: 3.240
Authors: Lena Hieggelke; Carina Heydt; Roberta Castiglione; Jan Rehker; Sabine Merkelbach-Bruse; Cristina Riobello; José Luis Llorente; Mario A Hermsen; Reinhard Buettner Journal: Cancers (Basel) Date: 2021-12-02 Impact factor: 6.639
Authors: Cristina García-Inclán; Alejandro López-Hernández; Marta Alonso-Guervós; Eva Allonca; Sira Potes; Santiago Melón; Fernando López; José Luis Llorente; Mario Hermsen Journal: Sci Rep Date: 2014-05-12 Impact factor: 4.379